Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.

PURPOSE DNA-hypomethylating agents are studied in combination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in myeloid neoplasias. A randomized, phase II trial with a 2 × 2 factorial design was conducted to investigate the effects of the histone deacetylase inhibitor valproate and all-trans retinoic acid (ATRA) in treatment-naive elderly patients with acute myeloid leukemia (AML). PATIENTS AND METHODS Two hundred patients (median age, 76 years; range, 61-92 years) ineligible for induction chemotherapy received decitabine (20 mg/m2 intravenously, days 1 to 5) alone (n = 47) or in combination with valproate (n = 57), ATRA (n = 46), or valproate + ATRA (n = 50). The primary endpoint was objective response, defined as complete and partial remission, tested at a one-sided significance level of α = .10. Key secondary endpoints were overall survival, event-free survival, and progression-free survival and safety. RESULTS The addition of ATRA resulted in a higher remission rate (21.9% with ATRA v 13.5% without ATRA; odds ratio, 1.80; 95% CI, 0.86 to 3.79; one-sided P = .06). For valproate, no effect was observed (17.8% with valproate v 17.2% without valproate; odds ratio, 1.06; 95% CI, 0.51 to 2.21; one-sided P = .44). Median overall survival was 8.2 months with ATRA v 5.1 months without ATRA (hazard ratio, 0.65; 95% CI, 0.48 to 0.89; two-sided P = .006). Improved survival was observed across risk groups, including patients with adverse cytogenetics, and was associated with longer response duration. With valproate, no survival difference was observed. Toxicities were predominantly hematologic, without relevant differences between the 4 arms. CONCLUSION The addition of ATRA to decitabine resulted in a higher remission rate and a clinically meaningful survival extension in these patients with difficult-to-treat disease, without added toxicity.

[1]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[2]  L. Bullinger,et al.  Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care , 2018, Leukemia.

[3]  C. Delpierre,et al.  Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey , 2018, Haematologica.

[4]  Ø. Bruserud,et al.  Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells , 2017, BMC Cancer.

[5]  M. Konopleva,et al.  Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome , 2017, Haematologica.

[6]  Nakul M. Shah,et al.  DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats , 2017, Nature Genetics.

[7]  S. Gore,et al.  Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings , 2017, Leukemia & lymphoma.

[8]  M. Christmann,et al.  Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells , 2016, Archives of Toxicology.

[9]  K. Döhner,et al.  All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study , 2016, Annals of Hematology.

[10]  Wei Wu,et al.  Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy , 2016, Annals of Hematology.

[11]  M. Beckmann,et al.  Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses , 2016, Cell.

[12]  H. Kantarjian,et al.  A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome , 2016, Leukemia.

[13]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[14]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[15]  M. Wetzler,et al.  Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. , 2015, Clinical lymphoma, myeloma & leukemia.

[16]  M. Scioli,et al.  Vitamin A, Cancer Treatment and Prevention: The New Role of Cellular Retinol Binding Proteins , 2015, BioMed research international.

[17]  J. Issa,et al.  Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia , 2015, Cancer.

[18]  T. Haferlach,et al.  Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia , 2015, Haematologica.

[19]  A. Ganser,et al.  Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group , 2015, Annals of Hematology.

[20]  M. Lübbert,et al.  Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat , 2013, PloS one.

[21]  K. Döhner,et al.  A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy , 2012, Haematologica.

[22]  S. Fröhling,et al.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.

[23]  H. Dombret,et al.  Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome , 2010, Oncotarget.

[24]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[25]  C. Bradbury,et al.  Elevated FOSB‐expression; a potential marker of valproate sensitivity in AML , 2009, British journal of haematology.

[26]  S. Fröhling,et al.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B , 2009, Haematologica.

[27]  M. Sorror,et al.  Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation , 2008, Cancer.

[28]  Jorge Cortes,et al.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.

[29]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[30]  Michael Rytting,et al.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.

[31]  C. Steidl,et al.  The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia , 2006, Cancer.

[32]  C. Schoch,et al.  Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia , 2005, Cancer.

[33]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.